Sun Pharma signs exclusive licensing deal for Lerodalcibep outside US, China
In short
Sun Pharma has signed an exclusive deal with LIB Therapeutics to make and sell Lerodalcibep everywhere except the US and China.
This could expand the drug’s reach, but the reporting does not give the price, timing, or approval details.
What the reporting says
Sun Pharma signed an exclusive licensing agreement with LIB Therapeutics to commercialize and manufacture Lerodalcibep worldwide, excluding the United States and China, according to the publisher summary. The available reporting does not say when the agreement was signed or provide financial terms. The deal could widen distribution, but approval status and sales potential are not stated.
Why it matters
Sun Pharma signed an exclusive licensing agreement with LIB Therapeutics to commercialize and manufacture Lerodalcibep worldwide, excluding the United States and China. The excerpt does not provide the timing, payment terms, or whether sales have started. The main named parties are Sun Pharma and LIB Therapeutics, and the result could affect drug availability in the licensed markets.